Shearman & Sterling advised Caris Life Sciences in the transaction.
The financing includes a $235 million equity investment co-led by Highland Capital Management and Coatue, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., OrbiMed, Millennium Management, Neuberger Berman, ClearBridge Investments, First Light Asset Management and other undisclosed investors. Sixth Street provided $75 million in debt and also participated in the equity round.
Headquartered in Irving, Texas, Caris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation.
Shearman & Sterling advised Caris Life Sciences with a team comprised of Robert Masella (Picture), J. Russel Denton, Ryan Bray, Gillian Emmett Moldowan, Jordan Altman, Jae H. Kim, Kara K. Quinn, Sarah Grinshtein, and Y. Jingjing Liang.
Involved fees earner: Jordan Altman – Shearman & Sterling; Ryan Bray – Shearman & Sterling; J. Russel Denton – Shearman & Sterling; Gillian Emmett Moldowan – Shearman & Sterling; Sarah Grinshtein – Shearman & Sterling; Jae Kim – Shearman & Sterling; Jingjing Liang – Shearman & Sterling; Robert Masella – Shearman & Sterling; Kara Quinn – Shearman & Sterling;
Law Firms: Shearman & Sterling;
Clients: Caris Life Sciences;